![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » AbbVie to Broaden Oncology Menu With $5.8B Stemcentrx Acquisition
AbbVie to Broaden Oncology Menu With $5.8B Stemcentrx Acquisition
May 4, 2016
AbbVie has agreed to acquire Stemcentrx for $5.8 billion in a deal intended to expand the company’s oncology pipeline.
AbbVie will obtain Stemcentrx’s lead asset Rovalpituzumab tesirine (Rova-T) and four additional early-stage clinical compounds to treat solid tumors.
Rova-T is a biomarker-specific antibody drug conjugate that targets the cancer stem cell protein DLL3, which is expressed in 80 percent of small-cell lung cancers. The therapy is being studied in the third-line setting for SCLC, for which there are no existing treatments.
Upcoming Events
-
21Oct